Clinical Trial Update: Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older [NA]

View source ↗

Summary

A terminated clinical trial evaluated the immunogenicity of Zostavax in adults aged 60 and older with antibody deficiency conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Specific Antibody Deficiency
• X-linked Agammaglobulinemia

Drugs mentioned

• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: University of South Florida | Conditions: Common Variable Immune Deficiency, Specific Antibody Deficiency | NA | Status: TERMINATED